相关实验视频
Updated: Jun 12, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
了解葡萄糖激酶激活剂作为抗糖尿病剂的新兴潜力
Anuradha Mehra1, Shubham Kumar1, Anu Mittal2
1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Jalandhar-Delhi G.T. Road, Punjab, 144411, India.
Pharmaceutical patent analyst
|September 24, 2024
概括
葡萄糖酶激活剂是激活葡萄糖酶酶的化合物,对于葡萄糖代谢至关重要. 最近的研究表明,针对针对糖尿病的这些新型候选药物的有希望的临床试验结果.
科学领域:
- 生物化学和酶学 生物化学和酶学
- 药品化学 药品化学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖酶酶是六酶家族的成员,通过催化葡萄糖酸化的速度限制步骤,在葡萄糖代谢中发挥关键作用.
- 葡萄糖激酶功能障碍或失活与糖尿病病理生理学有关.
- 葡萄糖激酶激活剂 (GKAs) 是旨在全结合并激活葡萄糖激酶的化合物.
研究的目的:
- 从2014年到2023年,审查关于葡萄糖激酶激活剂的专利和研究文献.
- 讨论正在开发用于药物发现的GKA的新型化学型.
- 突出GKA在临床试验中的进展及其报告的结果.
主要方法:
- 专利和科学出版物的文献综述 (2014-2023年).
- 对已识别的GKA进行结构-活动关系 (SAR) 分析.
- 讨论新型化学品的药物开发策略和临床试验数据.
主要成果:
- 识别和讨论针对葡萄糖酶的新型化学型.
- 在GKA开发方面有显著兴趣和进展的证据,包括进入临床试验.
- 从临床试验数据报告的成功结局表明了治疗潜力.
结论:
- 葡萄糖激酶激活剂代表了治疗糖尿病的有前途的治疗策略.
- 药物化学的最新进展已经产生了新的GKA化学型,具有潜在的临床实用性.
- 成功的临床试验数据强调了对GKA的显著治疗兴趣.
相关概念视频
Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
Oral Hypoglycemic Agents: Glinides
145
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
145
Oral Hypoglycemic Agents: Biguanides and Glitazones
182
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
182
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K

